# Major Recall Alert: Teva Octreotide for Injection Recalled Due to Potential Drug Quality Issues
Teva Canada Limited has issued a voluntary recall for all strengths of the prescription drug Octreotide for injection—10 mg/vial kit, 20 mg/vial kit, and 30 mg/vial kit. This precautionary measure comes after deficiencies in Good Manufacturing Practices (GMP) were identified at its foreign manufacturing site. GMP violations can lead to significant quality issues, including potential microbiological contamination, contamination with foreign particles, and inaccuracies in dosing.
This recall has raised serious health concerns, as compromised medication quality could result in health risks ranging from skin infections to severe allergic reactions. If you or a loved one is currently prescribed Teva Octreotide, read on for important information about this recall and how to protect your health.
## Why This Recall is Important
Good Manufacturing Practices (GMP) are essential guidelines that ensure medications meet rigorous quality and safety standards before they are sold. The deficiencies in GMP for Teva Octreotide raise several safety risks that could have a grave impact on patients relying on this medication. These safety risks include:
- **Infections at the injection site**, such as cellulitis or abscess formation.
- **Severe blood infections** that can be life-threatening.
- **Blood clots** and associated complications.
- **Hypersensitivity reactions**, including severe allergic reactions.
- **Inflammatory reactions or lumps** at the injection site.
- A **lack of therapeutic effectiveness**, potentially worsening the conditions the drug is meant to treat.
- **Symptoms of overdose**, such as hot flushes, increased urination, fatigue, depression, anxiety, lack of concentration, or exacerbated side effects.
Given these risks, Health Canada is actively overseeing Teva Canada Limited’s recall actions and reviewing its corrective and preventive measures. Public updates will be provided if additional risks are identified.
## Details of the Recall
- **Affected Product**:
- Teva Octreotide for injection 10 mg/vial - kit
- Teva Octreotide for injection 20 mg/vial - kit
- Teva Octreotide for injection 30 mg/vial - kit
- **Recall Reason**:
- Identified GMP deficiencies at a foreign manufacturing facility.
- Concerns include microbiological contamination, foreign particle contamination, and dosing inaccuracies.
- **Purpose of the Medication**:
- Treats hormone-related disorders like **acromegaly** (excess growth hormone).
- Manages severe diarrhea and flushing caused by certain tumors.
For an official statement, visit Health Canada’s recall page [here](https://recalls-rappels.canada.ca/en/alert-recall/teva-octreotide-injectable-suspension-recalled-due-potential-drug-quality-issues).
## What You Should Do
Patients currently using Teva Octreotide should take the following precautions:
1. **Stop using the product immediately** and consult your healthcare provider about alternative treatment options.
2. Check if your product is part of the affected lots by referring to the recall notice or contacting Teva Canada directly.
3. Report any adverse health effects experienced after using the medication to Health Canada’s MedEffect program.
Pharmacists and healthcare providers handling this medication are also advised to stop distributing it and return any remaining stock to the supplier.
## Stay Safe – Get Instant Recall Alerts
Your health and safety come first! To stay informed about critical recalls like this one, consider using the official Health Canada recall app. You'll receive instant updates on product recalls, enabling you to act quickly and protect yourself and your family. Don’t miss another vital health alert—**download the recall app today**.
For additional resources and further updates, visit the Health Canada recall website [here](https://recalls-rappels.canada.ca/en/alert-recall/teva-octreotide-injectable-suspension-recalled-due-potential-drug-quality-issues). Stay vigilant and proactive in safeguarding your health!